Patients received up to three doses of atezolizumab at a fixed dose of 1,200 mg every 21 days before undergoing surgical resection. The primary end point was the percentage of patients able to ...

Atezolizumab combined with targeted therapy improved median overall survival to 19 months in patients with anaplastic thyroid carcinoma (ATC). The longest survival was observed in the BRAF V600E ...

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...